Genetic disruption and pharmacological inhibition of galectin-3 attenuates cardiac fibrosis, LV dysfunction, and subsequent heart failure development. Drugs binding to galectin-3 may be potential therapeutic candidates for the prevention or reversal of heart failure with extensive fibrosis.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2012) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: